Bicycle Therapeutics Plc (BCYC)
3.715
+0.03
(+0.81%)
USD |
NASDAQ |
Sep 28, 16:00
3.75
+0.04
(+0.94%)
After-Hours: 16:43
Bicycle Therapeutics Research and Development Expense (TTM) : 226.38M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 226.38M |
| March 31, 2026 | 262.21M |
| December 31, 2025 | 275.99M |
| September 30, 2025 | 279.06M |
| June 30, 2025 | 270.82M |
| March 31, 2025 | 234.65M |
| December 31, 2024 | 216.21M |
| September 30, 2024 | 206.14M |
| June 30, 2024 | 193.61M |
| March 31, 2024 | 192.08M |
| December 31, 2023 | 181.64M |
| September 30, 2023 | 162.83M |
| June 30, 2023 | 146.92M |
| March 31, 2023 | 125.53M |
| December 31, 2022 | 100.40M |
| September 30, 2022 | 81.04M |
| Date | Value |
|---|---|
| June 30, 2022 | 63.54M |
| March 31, 2022 | 51.53M |
| December 31, 2021 | 46.66M |
| September 30, 2021 | 44.23M |
| June 30, 2021 | 40.37M |
| March 31, 2021 | 35.85M |
| December 31, 2020 | 33.90M |
| September 30, 2020 | 30.09M |
| June 30, 2020 | 28.54M |
| March 31, 2020 | 27.06M |
| December 31, 2019 | 25.63M |
| September 30, 2019 | 25.43M |
| June 30, 2019 | 25.04M |
| March 31, 2019 | 23.39M |
| December 31, 2018 | 20.79M |
| September 30, 2018 | 18.78M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Autolus Therapeutics Plc | 112.42M |
| Akari Therapeutics Plc | 4.869M |
| Cellectis SA | 82.95M |
| Biodexa Pharmaceuticals Plc | 6.997M |
| Mereo BioPharma Group Plc | 14.98M |